{"classes":[{"categories":[{"measurements":[{"comment":"Due to patients lost to follow up, patient withdrawal of consent and post ASCT therapies; there were less deaths on study than anticipated. Therefore, median OS was not reached.","groupId":"OG000","lowerLimit":"1.31","upperLimit":"117.88","value":"NA"},{"comment":"Due to patients lost to follow up, patient withdrawal of consent and post ASCT therapies; there were less deaths on study than anticipated. Therefore, median OS was not reached","groupId":"OG001","lowerLimit":"0.03","upperLimit":"119.23","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"165"},{"groupId":"OG001","value":"164"}],"units":"Participants"}],"description":"Time from date of randomization to date of death due to any cause","dispersionType":"Full Range","groups":[{"description":"brentuximab vedotin 1.8 mg/kg every 3 weeks by IV infusion","id":"OG000","title":"Brentuximab Vedotin"},{"description":"placebo every 3 weeks by IV infusion","id":"OG001","title":"Placebo"}],"paramType":"MEDIAN","populationDescription":"Intention-to-Treat analysis set","reportingStatus":"POSTED","timeFrame":"Up to approximately 10 years","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"months"}